Interleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis
Open Access
- 10 September 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- p. e77663
Abstract
Sepsis remains a global health crisis with high mortality, due to a paucity of reliable diagnostic markers for accurate risk stratification and precision management. Interleukin‐39 (IL‐39), a novel immunomodulatory cytokine, plays an important role in regulating the pathophysiology of immunity, metabolism, and et al. Here, we observed significantly elevated serum IL‐39 levels in septic patients at admission compared with non‐sepsis ICU patients and healthy controls across two independent cohorts. Furthermore, circulating IL‐39 concentrations could predict 28‐days survival in patients with sepsis. Single‐cell sequencing demonstrated that elevated IL‐39 was derived from macrophages during sepsis. Meanwhile, supplementation of IL‐39, via either recombinant protein (rmIL‐39) administration or macrophage‐specific AAV‐mediated overexpression, profoundly aggravates multiple organ dysfunction and damage in septic mice. Consistently, macrophage IL‐39 deficiency, via either macrophage‐conditional knockout or macrophage‐specific AAV‐mediated silence, protects against sepsis. Mechanistically, IL‐39 engages GP130 to trigger MAPK/P38 signaling, driving pro‐inflammatory cytokine production. Consequently, macrophage‐specific GP130 deletion abrogates IL‐39‐induced sepsis aggravation. Finally, pharmaceutical inhibition of IL‐39 with neutralizing antibodies can protect against sepsis. Together, these results highlight the dual clinical utility of IL‐39, as both a robust biomarker with independent prognostic value for sepsis patient stratification and a promising therapeutic strategy for sepsis.Keywords
Funding Information
- National Natural Science Foundation of China (82202378)
- National Natural Science Foundation of China (82270098)
This publication has 24 references indexed in Scilit:
- The role of IL-39 in autoimmune diseases: From general to immunopathogenesisCytokine, 2025
- Circulating interleukin-39 as a potential biomarker for rheumatoid arthritis diagnosisClinical Biochemistry, 2023
- Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wastingJournal of Cachexia, Sarcopenia and Muscle, 2021
- Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severityMultiple Sclerosis and Related Disorders, 2020
- Interleukin-6: designing specific therapeutics for a complex cytokineNature Reviews Drug Discovery, 2018
- Interleukin-30 (IL27p28) alleviates experimental sepsis by modulating cytokine profile in NKT cellsJournal of Hepatology, 2016
- A novel IL‐23p19/Ebi3 (IL‐39) cytokine mediates inflammation in Lupus‐like miceEuropean Journal of Immunology, 2016
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Why have clinical trials in sepsis failed?Trends in Molecular Medicine, 2014
- A role for IL-27p28 as an antagonist of gp130-mediated signalingNature Immunology, 2010